Envestnet Asset Management
BBIO icon

Envestnet Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Envestnet Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.89M Buy
105,993
+6,077
+6% +$426K ﹤0.01% 2107
2026
Q1 		$7.42M Buy
99,916
+69,021
+223% +$5M ﹤0.01% 2036
2025
Q4 		$2.36M Sell
30,895
-15,070
-33% -$989K ﹤0.01% 2709
2025
Q3 		$2.39M Buy
45,965
+6,478
+16% +$316K ﹤0.01% 2768
2025
Q2 		$1.71M Buy
39,487
+26,500
+204% +$964K ﹤0.01% 2934
2025
Q1 		$449K Buy
12,987
+61
+0.5% +$2.06K ﹤0.01% 3695
2024
Q4 		$355K Sell
12,926
-2,949
-19% -$76.2K ﹤0.01% 3791
2024
Q3 		$404K Sell
15,875
-10,814
-41% -$284K ﹤0.01% 3651
2024
Q2 		$676K Sell
26,689
-6,112
-19% -$167K ﹤0.01% 3279
2024
Q1 		$1.01M Sell
32,801
-3,558
-10% -$121K ﹤0.01% 3023
2023
Q4 		$1.47M Buy
36,359
+7,105
+24% +$213K ﹤0.01% 2652
2023
Q3 		$771K Buy
29,254
+8,090
+38% +$230K ﹤0.01% 3000
2023
Q2 		$364K Buy
21,164
+437
+2% +$6.58K ﹤0.01% 3385
2023
Q1 		$344K Buy
20,727
+8,595
+71% +$100K ﹤0.01% 3371
2022
Q4 		$92.4K Sell
12,132
-249
-2% -$2.38K ﹤0.01% 3825
2022
Q3 		$123K Buy
+12,381
New +$129K ﹤0.01% 3699

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Envestnet Asset Management's BBIO Position: Q2 2026 in Review

Envestnet Asset Management increased its BridgeBio Pharma (BBIO) stake by 6.1% in Q2 2026, buying an estimated $426K and bringing the position to 105,993 shares worth $7.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2107.

Envestnet Asset Management first reported a position in BBIO in Q3 2022 and has held it in 16 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Envestnet Asset Management held 105,993 shares of BridgeBio Pharma worth $7.89M as of Q2 2026.
  • Envestnet Asset Management bought 6,077 BridgeBio Pharma shares in Q2 2026, an estimated $426K.
  • BridgeBio Pharma made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2107 holding.
  • Envestnet Asset Management first reported a position in BridgeBio Pharma in Q3 2022 and has held it in 16 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.